Aspects of the pathogenesis of the Rauscher murine leukemia virus infection

Among the oncogenic viruses, Rauscher murine leukemia virus (R-MuLV) (RAUSCHER 1962) occupies a relatively prominent place in experimental neoplasia. Therefore, we performed a series of experiments to acquire more information about the morphological changes occurring during R-MuL V-induced infection, which is also called Rauscher disease of mice (FINK et a!. 1964). During these studies, we were able to determine the morphological expression of the cytopathic effects of R-MuLV and the neoplastic nature of Rauscher disease. Afterwards, the cytopathic effect of R-MuLV on adult and embryonic tissue was studied both light- and electron-microscopically. Finally, we made an attempt to develop a convenient method for the transplantation of hemopoietic cells infected with R-MuL V. This investigation led to the identification of mesenteric hemopoietic colonies. The occurrence of mesenteric hemopoietic colonies was studied in several strains of mice, and to complete the investigation also in Macaca fascicularis monkeys

Microscopic Studies Of The Foetal Lung Development In The OneHumped Camel (Camelus dromedarius) Obtained From Kano Abattoir

Eighty – seven foetal lung samples from camels (Camelus dromedarius) were collected at Kano abattoir to study lung development. Four phases of the lung development were observed as follows; pseudo-glandular phase was between 10.5 cm to 38.2 cm crown-rump length, with endodermal buds and prominent mesenchymal cells. Canalicular phase was observed between 38.7 cm to 62.2 cm  crownrump length and was characterized by thinning of the endodermal buds and invasion of capillaries. Saccular phase was noticed at 65.6 cm to 82.6 cm crown-rump length when thick intercellular septa were noticed. Alveolar phase was noticed between 85.9 cm to 121 cm crown-rump length when primitive alveolar was noticed. This study has established phases of lung development in the camel and serves as baseline information for scientific knowledge. Keywords: Foetal lung, camel (Camelus dromedarius), crown-rump length, lung development and Kano abattoir

Phytochemical, antifungal and acute toxicity studies of Mitracarpus scaber Zucc. whole plant extracts

Mitracarpus scaber have been reported in the treatment of various ailments such as ulcer, cancer, skin diseases etc. It is therefore important to investigate these plant parts to ascertain their therapeutic potentials. The Mitracarpus scaber whole plant was extracted with water and methanol, screened for their phytochemical properties and antifungal effects. The plant samples were also investigated for alkaloid, flavonoids, saponins, tannins and phenolic contents using quantitative techniques. The antifungal activities of the plant samples were tested against Candida albicans, Trichophyton mentagrophytes, Microsporum auduounii and Aspergillus flavus. The Minimum Inhibitory Concentration (MIC) and Minimum Fungicidal Concentration (MFC) of the extracts were also determined. Flavonoid, steroid, triterpenes, tannins, carbohydrate, glycoside, phenols were detected in both extracts while anthraquinones was absent. Alkaloid was detected in the aqueous extract but absent in methanol extract. Quantitatively, the phenols (97.0 mg/g) was the highest phytochemical detected in the plant while the lowest was alkaloid (9.2 mg/g). Toxicity of the samples was expressed as LD50, it was found above 5000 mg/kg and did not cause mortality in all the tested rats. Aqueous extract only showed inhibition on Candida albicans and Trichophyton mentagrophytes with no inhibition on Microsporum auduounii and Aspergillus flavus while ethanol extract only showed inhibition on Candida albicans with no inhibition on Microsporum auduounii, Trichophyton mentagrophytes and Aspergillus flavus at the lowest concentration 12.5 mg/ml. The aqueous extract has MIC and MFC of 12.5 mg/ml and 25 mg/ml respectively against Candidaalbicans and Trichophyton mentagrophytes. Thus, the traditional claims of the uses of the plants as antifungal agents were therefore supported

Pengaruh Faktor Keperilakuan Organisasi Terhadap Kegunaan Sistem Akuntansi Keuangan Daerah Di Kabupaten Klaten

This study, entitled "Effects of Organizational Behavioral Factors to Regional Financial Accounting System utilities in Klaten District". This study aims to determine, analyze and obtain empirical evidence about the influence of behavioral factors of the organization's financial accounting system usability area in the district of Klaten in accordance Permendagri 64 2014 Top 59 Amendment Regulation 2007. This study was conducted using a survey method with questionnaires. The study population was all the heads of the finance department at the office of Sub SKPD Klaten district. Data analysis was performed to test the validity and reliability, test classic assumptions and hypothesis testing with multiple linear regression method. This study uses primary data and obtained by distributing questionnaires to 60 respondents. The results showed that the behavioral variables organization (supervisor support, clarity of purpose, training) affects the area of financial accounting system usability. This shows that support for the boss, clarity of purpose and training can affect usability in realizing the area of financial accounting system is better in an agency

Ultra violet sensors based on nanostructured ZnO spheres in network of nanowires: a novel approach

The ZnO nanostructures consisting of micro spheres in a network of nano wires were synthesized by direct vapor phase method. X-ray Photoelectron Spectroscopy measurements were carried out to understand the chemical nature of the sample. ZnO nanostructures exhibited band edge luminescence at 383 nm. The nanostructure based ZnO thin films were used to fabricate UV sensors. The photoresponse measurements were carried out and the responsivity was measured to be 50 mA W−1. The rise and decay time measurements were also measured

Tracking development assistance for health and for COVID-19 : a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990-2050

Background The rapid spread of COVID-19 renewed the focus on how health systems across the globe are financed, especially during public health emergencies. Development assistance is an important source of health financing in many low-income countries, yet little is known about how much of this funding was disbursed for COVID-19. We aimed to put development assistance for health for COVID-19 in the context of broader trends in global health financing, and to estimate total health spending from 1995 to 2050 and development assistance for COVID-19 in 2020. Methods We estimated domestic health spending and development assistance for health to generate total health-sector spending estimates for 204 countries and territories. We leveraged data from the WHO Global Health Expenditure Database to produce estimates of domestic health spending. To generate estimates for development assistance for health, we relied on project-level disbursement data from the major international development agencies' online databases and annual financial statements and reports for information on income sources. To adjust our estimates for 2020 to include disbursements related to COVID-19, we extracted project data on commitments and disbursements from a broader set of databases (because not all of the data sources used to estimate the historical series extend to 2020), including the UN Office of Humanitarian Assistance Financial Tracking Service and the International Aid Transparency Initiative. We reported all the historic and future spending estimates in inflation-adjusted 2020 US$, 2020 US$ per capita, purchasing-power parity-adjusted US$per capita, and as a proportion of gross domestic product. We used various models to generate future health spending to 2050. Findings In 2019, health spending globally reached$8. 8 trillion (95% uncertainty interval [UI] 8.7-8.8) or $1132 (1119-1143) per person. Spending on health varied within and across income groups and geographical regions. Of this total,$40.4 billion (0.5%, 95% UI 0.5-0.5) was development assistance for health provided to low-income and middle-income countries, which made up 24.6% (UI 24.0-25.1) of total spending in low-income countries. We estimate that $54.8 billion in development assistance for health was disbursed in 2020. Of this,$13.7 billion was targeted toward the COVID-19 health response. $12.3 billion was newly committed and$1.4 billion was repurposed from existing health projects. $3.1 billion (22.4$2.4 billion (17.9%) was for supply chain and logistics. Only $714.4 million (7.7$1519 (1448-1591) per person in 2050, although spending across countries is expected to remain varied. Interpretation Global health spending is expected to continue to grow, but remain unequally distributed between countries. We estimate that development organisations substantially increased the amount of development assistance for health provided in 2020. Continued efforts are needed to raise sufficient resources to mitigate the pandemic for the most vulnerable, and to help curtail the pandemic for all. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd.Peer reviewe

Track D Social Science, Human Rights and Political Science

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/138414/1/jia218442.pd

Global Retinoblastoma Presentation and Analysis by National Income Level

Importance: Early diagnosis of retinoblastoma, the most common intraocular cancer, can save both a child's life and vision. However, anecdotal evidence suggests that many children across the world are diagnosed late. To our knowledge, the clinical presentation of retinoblastoma has never been assessed on a global scale. Objectives: To report the retinoblastoma stage at diagnosis in patients across the world during a single year, to investigate associations between clinical variables and national income level, and to investigate risk factors for advanced disease at diagnosis. Design, Setting, and Participants: A total of 278 retinoblastoma treatment centers were recruited from June 2017 through December 2018 to participate in a cross-sectional analysis of treatment-naive patients with retinoblastoma who were diagnosed in 2017. Main Outcomes and Measures: Age at presentation, proportion of familial history of retinoblastoma, and tumor stage and metastasis. Results: The cohort included 4351 new patients from 153 countries; the median age at diagnosis was 30.5 (interquartile range, 18.3-45.9) months, and 1976 patients (45.4) were female. Most patients (n = 3685 84.7%) were from low-and middle-income countries (LMICs). Globally, the most common indication for referral was leukocoria (n = 2638 62.8%), followed by strabismus (n = 429 10.2%) and proptosis (n = 309 7.4%). Patients from high-income countries (HICs) were diagnosed at a median age of 14.1 months, with 656 of 666 (98.5%) patients having intraocular retinoblastoma and 2 (0.3%) having metastasis. Patients from low-income countries were diagnosed at a median age of 30.5 months, with 256 of 521 (49.1%) having extraocular retinoblastoma and 94 of 498 (18.9%) having metastasis. Lower national income level was associated with older presentation age, higher proportion of locally advanced disease and distant metastasis, and smaller proportion of familial history of retinoblastoma. Advanced disease at diagnosis was more common in LMICs even after adjusting for age (odds ratio for low-income countries vs upper-middle-income countries and HICs, 17.92 95% CI, 12.94-24.80, and for lower-middle-income countries vs upper-middle-income countries and HICs, 5.74 95% CI, 4.30-7.68). Conclusions and Relevance: This study is estimated to have included more than half of all new retinoblastoma cases worldwide in 2017. Children from LMICs, where the main global retinoblastoma burden lies, presented at an older age with more advanced disease and demonstrated a smaller proportion of familial history of retinoblastoma, likely because many do not reach a childbearing age. Given that retinoblastoma is curable, these data are concerning and mandate intervention at national and international levels. Further studies are needed to investigate factors, other than age at presentation, that may be associated with advanced disease in LMICs. © 2020 American Medical Association. All rights reserved